A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • STATUS
    Not Recruiting
  • participants needed
    940
  • sponsor
    AbbVie
Updated on 19 June 2021
Investigator
AbbVie_Call Center
Primary Contact
Universitaetsklinikum Erlangen /ID# 159315 (8.7 mi away) Contact
+760 other location
abdominal pain
risankizumab

Summary

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).

Details
Condition Inflammatory bowel disease, Crohn's Disease, Crohn's Disease (Pediatric)
Treatment placebo for risankizumab, risankizumab IV, risankizumab SC
Clinical Study IdentifierNCT03105128
SponsorAbbVie
Last Modified on19 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note